News and Trends 25 Oct 2017
Shire’s Hemophilia Gene Therapy Boosted by Orphan Drug Designation
The FDA has granted orphan drug designation to Shire’s hemophilia A gene therapy, giving it the boost it needs to catch up with others in the field. Shire specializes in the development of drugs for rare diseases, including hemophilia A – a bleeding disorder caused by a lack of clotting factor VIII activity in the […]